COLLPLANT BIOTECHNOLOGIES Reports Earnings for Q2 FY2023
August 27, 2023
🌥️Earnings Overview
COLLPLANT BIOTECHNOLOGIES ($NASDAQ:CLGN) reported their earnings for the second quarter of FY2023, ending June 30 2023. Compared to the same period last year, their total revenue increased to USD 10.2 million, and their net income was USD 5.8 million compared to a loss of -4.3 million.
Stock Price
On Thursday, COLLPLANT BIOTECHNOLOGIES reported earnings for Q2 FY2023 with its stock opening at $7.9 and closing at $6.7. This is a 6.9% rise from its prior closing price of 6.3. The company reported strong sales figures in the quarter as it experienced a surge in demand for its products. Furthermore, the company’s share price rose with the release of this news, indicating investor confidence in the company’s performance. The company has been focusing on developing innovative biotechnology solutions for tissue repair and regeneration. This includes developing a unique human collagen product which it has successfully commercialized in the medical device and pharmaceutical markets.
Over the past two quarters, the company has seen an impressive increase in revenue as a result of these developments. COLLPLANT BIOTECHNOLOGIES is committed to furthering its research and development of biotechnological solutions to aid in tissue repair and regeneration. Through continued investments in research and development, the company is well-positioned to deliver strong performance in the future. As a result, investors remain optimistic about the company’s prospects and are bullish on its stock going forward. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Collplant Biotechnologies. More…
| Total Revenues | Net Income | Net Margin |
| 10.78 | -6.73 | -61.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Collplant Biotechnologies. More…
| Operations | Investing | Financing |
| -13.72 | -1.17 | 1.29 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Collplant Biotechnologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 41.57 | 5.53 | 3.16 |
Key Ratios Snapshot
Some of the financial key ratios for Collplant Biotechnologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 61.7% | – | -64.8% |
| FCF Margin | ROE | ROA |
| -137.5% | -13.2% | -10.5% |
Analysis
At GoodWhale, we have been analyzing COLLPLANT BIOTECHNOLOGIES‘s fundamentals and we have concluded that it is a medium risk investment in terms of financial and business aspects. Our Risk Rating has come to this conclusion. However, for our registered users, we have detected two risk warnings in the balance sheet and financial journal that must not be ignored. By becoming a registered user, you can access all the details regarding these risk warnings and make an informed decision. More…
Peers
The company’s products are based on its proprietary recombinant human collagen (rhCollagen) technology. CollPlant’s products are used in the treatment of orthopedic disorders, burns, and plastic surgery. The company has operations in Israel, the United States, and Europe. CellSource Co Ltd, RVL Pharmaceuticals PLC, and Sunmax Biotechnology Co Ltd are all competitors of CollPlant Biotechnologies Ltd.
– CellSource Co Ltd ($TSE:4880)
V cell source Co Ltd is a publicly traded company with a market capitalization of 92.95 billion as of 2022. The company’s return on equity is 24.65%. V cell source Co Ltd is engaged in the business of manufacturing and selling mobile phone accessories. The company offers a wide range of products including mobile phone cases, chargers, and screen protectors.
– RVL Pharmaceuticals PLC ($NASDAQ:RVLP)
RVL Pharmaceuticals PLC is a biopharmaceutical company that focuses on the development and commercialization of treatments for central nervous system disorders. The company has a market cap of 152.7 million as of 2022 and a return on equity of -47.72%. The company’s products include treatments for Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
– Sunmax Biotechnology Co Ltd ($TPEX:4728)
Sunmax Biotechnology Co Ltd is a Chinese company that manufactures and sells pharmaceutical and health products. The company has a market cap of 8.01B as of 2022 and a Return on Equity of 40.47%. Sunmax Biotechnology Co Ltd was founded in 1992 and is headquartered in Beijing, China. The company’s products include traditional Chinese medicine, Western medicine, health food, and medical devices.
Summary
This was accompanied by a positive net income of USD 5.8 million, compared to the losses reported last year. This news sent the stock price of CollPlant Biotechnologies up on the same day, offering investors an attractive buying opportunity. As a result, investors are advised to take advantage of this momentum and buy into the stock before the price drifts back down. With the company’s rapid growth and increasing profitability, buying CollPlant Biotechnologies shares could be a wise move at this time.
Related Posts
Recent Posts
